Cyllene Therapeutics has expanded its leadership team by appointing Alyssa Levin to its Board of Directors and Chair of the Audit Committee, along with Clara Cambon-Thiebaud as VP of Regulatory Affairs and Céline Breda as VP of Chemistry, Manufacturing and Controls. These strategic hires aim to support the late-stage clinical development of their lead candidate, EG110A, targeting neurogenic bladder-related incontinence. The additions bring deep expertise in finance, regulatory affairs, and biologics manufacturing, positioning Cyllene Tx to advance its innovative HSV-1 vector technology and pipeline. This move is critical as the company prepares for next phases of growth and clinical progress.
Valeo has decided to exercise its make-whole redemption option to repay €750 million of its 5.375% Sustainability Linked Bonds due in May 2027. The redemption will occur in full on August 24, 2026, following a recent bond issuance aimed at financing ...
Valeo has decided to exercise its option for an early redemption (make-whole redemption) of its €750 million bonds bearing a 5.375% coupon due in May 2027. The redemption will take place on August 24, 2026, funded by proceeds from a recently issued €...
The global crop insurance market, valued at $48.50 billion in 2025, is projected to reach $106.23 billion by 2035, growing at a CAGR of 8.19%. This growth is driven by increasing climate variability, extreme weather events, and the need to protect fa...
On July 23, 2026, Michelin executed a buyback of 194,319 ordinary shares at an average price of €33.68 per share. The shares were repurchased over-the-counter through multiple financial institutions with the objective of cancelling them. This move is...
On July 23, 2026, Michelin executed a share buyback program, repurchasing 194,319 of its ordinary shares at an average price of €33.68 per share. The shares were bought through over-the-counter transactions involving several financial institutions an...
